LCTX · Lineage Cell Therapeutics Inc
United States · RS rating 34 · As of 2026-11-03
| Price | 1.01 USD |
|---|---|
| 1-day change | +0.0% |
| RS rating (overall / 1M / 3M / 12M) | 34 / 79 / 43 / 23 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 26 / 7 / 28 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | +79.5% |
| Distance from 52-week high | +48.5% |
| Market cap (USD) | $388.6M |